{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06327711",
            "orgStudyIdInfo": {
                "id": "BL77"
            },
            "organization": {
                "fullName": "Abbott Nutrition",
                "class": "INDUSTRY"
            },
            "briefTitle": "Benefits of Nutritional Ingredients for Type 2 Diabetes",
            "officialTitle": "Proof of Concept Study: Long-term Benefits of a Blend of Nutritional Ingredients for Type 2 Diabetes",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "benefits-of-nutritional-ingredients-for-type-diabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-07",
            "studyFirstSubmitQcDate": "2024-03-18",
            "studyFirstPostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Abbott Nutrition",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective randomized, double-blinded, parallel design study to evaluate the benefits of long-term consumption of two experimental blends of liquid supplements."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetes type2"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "2 groups, non-crossover",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 114,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CHO Blend",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Group will consume a ready to feed CHO blend beverage",
                    "interventionNames": [
                        "Other: Control: CHO Blend"
                    ]
                },
                {
                    "label": "CHO Blend plus AN100",
                    "type": "EXPERIMENTAL",
                    "description": "Group will consume a ready to feed CHO plus AN100 beverage",
                    "interventionNames": [
                        "Other: Experimental: CHO Blend plus AN100"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Control: CHO Blend",
                    "description": "2 servings as a snack or between meals morning and evening",
                    "armGroupLabels": [
                        "CHO Blend"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Experimental: CHO Blend plus AN100",
                    "description": "2 servings as a snack or between meals morning and evening",
                    "armGroupLabels": [
                        "CHO Blend plus AN100"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Matsuda Index",
                    "description": "Change in insulin sensitivity",
                    "timeFrame": "Baseline to week 12"
                },
                {
                    "measure": "Fasted Glucose",
                    "description": "Change in fasted glucose levels overtime",
                    "timeFrame": "Baseline week 4, week 8 and week 12"
                },
                {
                    "measure": "Fasted Insulin",
                    "description": "Change in fasted insulin levels overtime",
                    "timeFrame": "Baseline week 4, week 8 and week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Body Weight",
                    "description": "Changes in body weight",
                    "timeFrame": "Baseline up to 12 weeks"
                },
                {
                    "measure": "Body Composition Measurements",
                    "description": "Changes in bio electrical impendence analysis (BIA)",
                    "timeFrame": "Baseline up to 12 weeks"
                },
                {
                    "measure": "Continuous Glucose Monitoring",
                    "description": "Change in glycemic variability",
                    "timeFrame": "Baseline, week 1 to week 2, week 11 and 12"
                },
                {
                    "measure": "Glycated Hemoglobin",
                    "description": "Change in hemoglobin A1c",
                    "timeFrame": "Baseline week 4, week 8 and week 12"
                },
                {
                    "measure": "Resting Energy Expenditure (REE)",
                    "description": "Changes in REE",
                    "timeFrame": "Baseline to week 12"
                },
                {
                    "measure": "Microbiome - Fecal",
                    "description": "Changes in fecal microbiome",
                    "timeFrame": "Baseline week 2, week 4, week 8 and week 12"
                },
                {
                    "measure": "Microbiome - Saliva",
                    "description": "Changes in saliva microbiome",
                    "timeFrame": "Baseline week 2, week 4, week 8 and week 12"
                },
                {
                    "measure": "Waist Circumference",
                    "description": "Changes in waist circumference",
                    "timeFrame": "Baseline up to 12 weeks"
                },
                {
                    "measure": "Hip Circumference",
                    "description": "Changes in hip circumstance",
                    "timeFrame": "Baseline up to 12 weeks"
                },
                {
                    "measure": "Conicity Index",
                    "description": "Changes in conicity index",
                    "timeFrame": "Baseline up to 12 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Blood Pressure",
                    "description": "Systolic and Diastolic",
                    "timeFrame": "Baseline week 4, week 8 and week 12"
                },
                {
                    "measure": "Accelerometry Data",
                    "description": "Change in accelerometer daily activities",
                    "timeFrame": "Baseline to week 12"
                },
                {
                    "measure": "Diabetes Distress Scale",
                    "description": "Participant assessed 29 questions rated from 1 to 5 were higher number if less favorable",
                    "timeFrame": "Baseline to week 12"
                },
                {
                    "measure": "Dietary Intake",
                    "description": "Energy and macronutrient intake calculated from participant reported diary",
                    "timeFrame": "Baseline to week 12"
                },
                {
                    "measure": "Blood biomarkers - inflammation",
                    "description": "Change in protein marker of inflammation such as CRP",
                    "timeFrame": "Time Frame: Baseline to week 12"
                },
                {
                    "measure": "Urine biomarkers - inflammation",
                    "description": "Change in protein marker of inflammation such as CRP",
                    "timeFrame": "Time Frame: Baseline to week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has type 2 diabetes\n* Taking a maximum of 3 oral anti-diabetic drugs, one must be Metformin.\n* HbA1c \u2265 6.5% and \u2264 9.5% based on blood sample obtained at Screening Visit\n* BMI \\> 27.0 and \\< 35.0 kg/m2\n* Weight is stable for the two months prior to Baseline visit\n* Either male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to Baseline Visit\n* If on chronic medication type and dose were constant for at least two months prior to the baseline Visit, and medication will continue throughout the study\n* Willingness to follow the protocol as described, including consumption of study product and completing any forms/questionnaires needed throughout the study\n* Four-week washout period between completion of a previous research study that required ingestion of any study food or drug and start in current study\n* The participant is willing to refrain from taking non-study diabetes-specific oral nutritional formulas during the study\n\nExclusion Criteria:\n\n* Use of exogenous insulin or GLP1 agonists\n* Follows a non-typical eating pattern such as very low carbohydrate diet\n* Pregnant or attempting to conceive\n* Confirmed type 1 diabetes and/or history of diabetic ketoacidosis\n* Current infection inpatient surgery or received systemic corticosteroid treatment in last 3 months; or received antibiotics in last 3 weeks\n* Has current active malignant disease or treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma\n* Significant cardiovascular event within 6 months prior or history of congestive heart failure\n* End-stage organ failure or is post-organ transplant\n* Current or history of renal disease, on dialysis or severe gastroparesis\n* Diagnosed hepatic disease or late stage liver fibrosis. Participants with prevalent angina will not be excluded.\n* Had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery\n* Chronic, contagious, infectious disease\n* Eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or any other conditions that may interfere with study product consumption or compliance with study protocol procedures\n* Taking any herbals, dietary supplements, or medications during the past four weeks prior to baseline visit that could profoundly affect blood glucose, body weight, muscle, metabolism, appetite or microbiome incretin mimetics, other drugs indicated for weight loss, cannabis, glucocorticoids, probiotic supplements). Those who have stopped using such supplements/ medications for \u22654 weeks prior to baseline need not be excluded).\n* Using diabetes-specific oral nutritional supplements(s), defined as more than one eating occasion per week within the past 4 weeks (those users who can stop using such products for \u22654 weeks before baseline visit need not be excluded)\n* Actively enrolled in a weight loss program\n* Clotting or bleeding disorders\n* Blood or blood-related diseases\n* Blood transfusion within the last 3 weeks\n* Allergic or intolerant to any ingredient found in the study products\n* Engages in strenuous exercise duration of 1 hour or longer, 3 or more times per week\n* Participates in another study that has not been approved as a concomitant study by Abbott Nutrition\n* Participant has skin lesions hyperhidrosis, eczema, psoriasis, scarring, tattoos, redness, infection or edema at the application sites that could interfere with device placement or accuracy of interstitial glucose measurements",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kristen DeLuca",
                    "role": "CONTACT",
                    "phone": "614-624-5455",
                    "email": "kristen.deluca@abbott.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Suzette Pereira",
                    "affiliation": "Abbott Nutrition",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Kent State University",
                    "city": "Kent",
                    "state": "Ohio",
                    "zip": "44242",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.15367,
                        "lon": -81.35789
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003924",
                    "term": "Diabetes Mellitus, Type 2"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7119",
                    "name": "Diabetes Mellitus, Type 2",
                    "asFound": "Diabetes Type 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}